The Institute of Cancer Research
Companion diagnostic assays for personalised therapies in gastrointestinal cancers that use robust gene-expression biomarkers.
Colorectal cancer is the second leading cause of death for cancer worldwide, with more than 800,000 deaths annually. Precision medicine and immunotherapy have been extremely successful in treating multiple types of cancer; unfortunately, only minor effects have been seen in the vast majority of colorectal cancer patients. Part of this failure is due to the lack of robust biomarkers that can easily be tested to facilitate treatment decisions.
We have identified molecular biomarkers (Sadanandam et al, Nature Medicine 2013) which have been patented, to develop an easy-to-use test to predict the type of response to the only available targeted agents in the UK for this highly lethal disease (anti epidermal growth factor receptor drugs) (Ragulan et al, bioRxiv 2017, Fontana et al, ascopubs.org 2018). The technology used for the test is widely available in pathology laboratories and has a clinically-relevant turn-around time for routine clinical application; it is performed on already available diagnostic tissue (no need for further invasive tests or biopsies in patients). These characteristics are particularly suitable for prospective validation.
Once validated in a clinically accredited laboratory, we envisage the test will directly impact on patients’ care. The use of a robust selection method, such as this test, will screen for patients who will not benefit from these drugs avoiding unnecessary toxicities and time spent in hospital instead of with family and friends in last months of their life. This will also ultimately result in the redistribution of health care funding to ensure that all patients with a high likelihood of a positive response will have access to these drugs beyond current restrictions, with an overall cost reduction for healthcare systems and improved patient outcomes.
Apply for Cohort Four
Focusing on novel solutions that address the Future of Pain our Challenge Accelerator Programme offers a salary replacement to take six-months (full-time) away from the lab to develop a medical technology into a business venture. The programme offers entrepreneurship masterclasses, specialist advice, access to co-working space and an allowance for travel and consumables (up to £45,000).Applications Closed